Hofseth BioCare ASA (HOFBF)
USD 0.1
(0.0%)
USD 0.1
(0.0%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 390.11 Million USD | 828.8% |
| 2022 | 42 Million NOK | -10.85% |
| 2021 | 47.11 Million NOK | -12.14% |
| 2020 | 53.62 Million NOK | 60.82% |
| 2019 | 33.34 Million NOK | -82.26% |
| 2018 | 187.94 Million NOK | 2.01% |
| 2017 | 184.23 Million NOK | 15.62% |
| 2016 | 159.35 Million NOK | -17.58% |
| 2015 | 193.34 Million NOK | -11.25% |
| 2014 | 217.86 Million NOK | 6.25% |
| 2013 | 205.05 Million NOK | 31.75% |
| 2012 | 155.63 Million NOK | -1.72% |
| 2011 | 158.36 Million NOK | 67.48% |
| 2010 | 94.55 Million NOK | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q2 | 36.07 Million USD | -1.33% |
| 2024 Q1 | 36.1 Million USD | 0.15% |
| 2023 Q2 | 38.24 Million USD | 2.4% |
| 2023 Q3 | 37.55 Million USD | -1.81% |
| 2023 Q4 | 38.29 Million USD | 1.99% |
| 2023 Q1 | 37.34 Million USD | -11.09% |
| 2023 FY | 390.11 Million USD | 828.8% |
| 2022 Q4 | 42 Million NOK | 8.55% |
| 2022 Q1 | 45.17 Million NOK | -4.12% |
| 2022 Q2 | 38.21 Million NOK | -15.4% |
| 2022 Q3 | 38.69 Million NOK | 1.25% |
| 2022 FY | 42 Million NOK | -10.85% |
| 2021 Q1 | 51.93 Million NOK | -88.69% |
| 2021 FY | 47.11 Million NOK | -12.14% |
| 2021 Q2 | 53.23 Million NOK | 2.51% |
| 2021 Q4 | 47.11 Million NOK | -6.96% |
| 2021 Q3 | 50.63 Million NOK | -4.88% |
| 2020 FY | 53.62 Million NOK | 60.82% |
| 2020 Q1 | 293.66 Million NOK | 0.22% |
| 2020 Q2 | 306.87 Million NOK | 4.5% |
| 2020 Q3 | 293.28 Million NOK | -4.43% |
| 2020 Q4 | 459.13 Million NOK | 56.55% |
| 2019 Q4 | 293.01 Million NOK | -11.35% |
| 2019 Q1 | 245.09 Million NOK | 30.41% |
| 2019 Q2 | 228.89 Million NOK | -6.61% |
| 2019 FY | 33.34 Million NOK | -82.26% |
| 2019 Q3 | 330.54 Million NOK | 44.41% |
| 2018 Q3 | 196.06 Million NOK | 29.66% |
| 2018 Q2 | 151.2 Million NOK | -0.33% |
| 2018 Q1 | 151.7 Million NOK | -17.66% |
| 2018 FY | 187.94 Million NOK | 2.01% |
| 2018 Q4 | 187.94 Million NOK | -4.14% |
| 2017 Q4 | 184.23 Million NOK | 22.18% |
| 2017 Q3 | 150.79 Million NOK | 5.7% |
| 2017 Q2 | 142.66 Million NOK | -22.06% |
| 2017 FY | 184.23 Million NOK | 15.62% |
| 2017 Q1 | 183.04 Million NOK | 14.87% |
| 2016 Q4 | 159.35 Million NOK | -16.56% |
| 2016 FY | 159.35 Million NOK | -17.58% |
| 2016 Q3 | 190.99 Million NOK | 20.87% |
| 2016 Q2 | 158.01 Million NOK | -3.93% |
| 2016 Q1 | 164.46 Million NOK | -14.94% |
| 2015 Q2 | 241.75 Million NOK | 13.5% |
| 2015 FY | 193.34 Million NOK | -11.25% |
| 2015 Q3 | 227.58 Million NOK | -5.86% |
| 2015 Q1 | 213 Million NOK | -2.23% |
| 2015 Q4 | 193.34 Million NOK | -15.05% |
| 2014 Q1 | 211.08 Million NOK | 2.94% |
| 2014 FY | 217.86 Million NOK | 6.25% |
| 2014 Q4 | 217.86 Million NOK | -6.92% |
| 2014 Q2 | 226.61 Million NOK | 7.36% |
| 2014 Q3 | 234.07 Million NOK | 3.29% |
| 2013 Q4 | 205.05 Million NOK | 0.07% |
| 2013 Q3 | 204.91 Million NOK | -0.65% |
| 2013 FY | 205.05 Million NOK | 31.75% |
| 2013 Q2 | 206.25 Million NOK | -2.72% |
| 2013 Q1 | 212.03 Million NOK | 36.23% |
| 2012 Q1 | 147.96 Million NOK | -6.57% |
| 2012 FY | 155.63 Million NOK | -1.72% |
| 2012 Q2 | 155.06 Million NOK | 4.8% |
| 2012 Q4 | 155.63 Million NOK | -12.79% |
| 2012 Q3 | 178.47 Million NOK | 15.09% |
| 2011 FY | 158.36 Million NOK | 67.48% |
| 2011 Q3 | 125.4 Million NOK | 0.0% |
| 2011 Q4 | 158.36 Million NOK | 26.29% |
| 2010 FY | 94.55 Million NOK | 0.0% |
| 2010 Q4 | 94.55 Million NOK | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| Eiger BioPharmaceuticals, Inc. | 38.84 Million USD | -904.245% |
| Nanobac Pharmaceuticals, Incorporated | 7.21 Million USD | -5303.488% |
| SQZ Biotechnologies Company | 107.18 Million USD | -263.961% |
| Evofem Biosciences, Inc. | 10.55 Million USD | -3596.409% |
| Santhera Pharmaceuticals Holding AG | 130.21 Million USD | -199.606% |
| Mesoblast Limited | 667.9 Million USD | 41.59% |
| Propanc Biopharma, Inc. | 72.36 Thousand USD | -538999.012% |
| Genus plc | 1.02 Billion USD | 62.084% |
| VioQuest Pharmaceuticals, Inc. | 1.35 Million USD | -28620.001% |
| CNBX Pharmaceuticals Inc. | 499.03 Thousand USD | -78074.051% |
| Marizyme, Inc. | 22.01 Million USD | -1672.054% |
| ContraFect Corporation | 20.67 Million USD | -1786.547% |
| Nymox Pharmaceutical Corporation | 627 Thousand USD | -62119.936% |
| PsyBio Therapeutics Corp. | 390.36 Thousand USD | -99836.726% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 382.17 Thousand USD | -101978.095% |
| Intellipharmaceutics International Inc. | 1.43 Million USD | -27142.338% |
| AXIM Biotechnologies, Inc. | 4.14 Million USD | -9309.477% |
| MultiCell Technologies, Inc. | 126.22 USD | -309078492.933% |
| Accustem Sciences Inc. | 939.68 Thousand USD | -41415.757% |
| RVL Pharmaceuticals plc | 128.51 Million USD | -203.571% |
| EV Biologics, Inc. | 431.71 Thousand USD | -90265.149% |
| Q BioMed Inc. | 3.51 Million USD | -10997.059% |
| Emmaus Life Sciences, Inc. | 35.17 Million USD | -1008.954% |
| Neon Bloom, Inc. | 770.64 Thousand USD | -50522.466% |
| Mosaic ImmunoEngineering Inc. | 261.27 Thousand USD | -149212.416% |
| Biomind Labs Inc. | 73.81 Thousand USD | -528380.473% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Pharming Group N.V. | 462.85 Million USD | 15.714% |
| Oncotelic Therapeutics, Inc. | 30.01 Million USD | -1199.749% |
| Skye Bioscience, Inc. | 11.94 Million USD | -3167.216% |
| Therapeutic Solutions International, Inc. | 3.31 Million USD | -11675.357% |
| THC Farmaceuticals, Inc. | 2.74 Million USD | -14105.077% |
| Arch Therapeutics, Inc. | 1.95 Million USD | -19822.439% |
| IMV Inc. | 31.33 Million USD | -1145.043% |
| Acro Biomedical Co., Ltd. | 687.48 Thousand USD | -56645.737% |
| Curative Biotechnology, Inc. | 2.6 Million USD | -14886.155% |
| GB Sciences, Inc. | 103.44 Thousand USD | -377037.913% |
| Alpha Cognition Inc. | 2.45 Million USD | -15809.134% |
| HST Global, Inc. | 1526.00 USD | -25564709.961% |
| CSL Limited | 38.02 Billion USD | 98.974% |
| Halberd Corporation | 10.13 Thousand USD | -3850645.237% |
| Enzolytics Inc. | 361.7 Million USD | -7.855% |
| Resverlogix Corp. | 8.11 Million USD | -4707.381% |
| Affymax, Inc. | 7.44 Million USD | -5141.421% |
| SYBLEU INC | 330.46 Thousand USD | -117950.462% |
| Nuo Therapeutics, Inc. | 1.87 Million USD | -20674.437% |
| argenx SE | 4.54 Billion USD | 91.412% |
| MetaStat, Inc. | - USD | -Infinity% |
| Northwest Biotherapeutics, Inc. | 27.94 Million USD | -1296.074% |
| Enzon Pharmaceuticals, Inc. | 47.7 Million USD | -717.825% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| RespireRx Pharmaceuticals Inc. | 22.78 Thousand USD | -1712375.308% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | 8.94 Million USD | -4259.283% |
| AVAX Technologies, Inc. | 7.37 Million USD | -5188.202% |
| Zenith Capital Corp. | 7410.00 USD | -5264663.833% |
| Genscript Biotech Corporation | 3.38 Billion USD | 88.48% |
| Ember Therapeutics, Inc. | 184.00 USD | -212021095.652% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 321.8 Thousand USD | -121128.007% |
| WPD Pharmaceuticals Inc. | 261.36 Thousand USD | -149162.714% |
| American Oriental Bioengineering, Inc. | 446.3 Million USD | 12.59% |
| Provectus Biopharmaceuticals, Inc. | 1.44 Million USD | -26826.244% |
| Adynxx, Inc. | - USD | -Infinity% |
| Helix BioMedix, Inc. | 3.02 Million USD | -12796.129% |
| GlobeStar Therapeutics Corporation | - USD | -Infinity% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 52.7 Million USD | -640.25% |
| Cotinga Pharmaceuticals Inc. | 927.96 Thousand USD | -41940.452% |
| BioStem Technologies, Inc. | 14.56 Million USD | -2579.335% |
| ONE Bio Corp. | 70.08 Million USD | -456.633% |
| Reve Technologies, Inc. | 57.09 Thousand USD | -683192.465% |
| Burzynski Research Institute, Inc. | 2310.00 USD | -16888168.398% |
| Wesana Health Holdings Inc. | 987.96 Thousand USD | -39387.048% |
| Agentix Corp. | 261.39 Thousand USD | -149146.725% |
| LadRx Corporation | 2.3 Million USD | -16803.767% |
| Cell Source, Inc. | 195.17 Thousand USD | -199785.741% |
| ProtoKinetix, Incorporated | 480.55 Thousand USD | -81080.588% |
| Regen BioPharma, Inc. | 353.61 Thousand USD | -110222.468% |
| Regen BioPharma, Inc. | 353.61 Thousand USD | -110222.468% |
| NovAccess Global Inc. | 62.24 Thousand USD | -626617.324% |
| Endonovo Therapeutics, Inc. | 639.65 Thousand USD | -60888.875% |
| Itoco Inc. | 1.4 Million USD | -27764.21% |
| Rasna Therapeutics, Inc. | 95.65 Thousand USD | -407731.105% |
| Pathfinder Cell Therapy, Inc. | 106 Thousand USD | -367936.792% |
| Kadimastem Ltd | 2.3 Million USD | -16831.66% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Institute of Biomedical Research Corp. | 76.35 Thousand USD | -510834.594% |
| CytoDyn Inc. | 11.13 Million USD | -3403.224% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | 142.97 Thousand USD | -272763.917% |
| Mobile Lads Corp. | 52.00 USD | -750228746.154% |
| NanoSphere Health Sciences Inc. | 17.88 Thousand USD | -2181773.602% |
| Qrons Inc. | 420.00 USD | -92885376.19% |
| Alseres Pharmaceuticals, Inc. | 385.47 Thousand USD | -101105.798% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| Nascent Biotech, Inc. | 552.12 Thousand USD | -70558.371% |
| Rebus Holdings, Inc. | 5000.00 USD | -7802280.0% |
| ImmunoCellular Therapeutics, Ltd. | 409.42 Thousand USD | -95185.305% |
| International Stem Cell Corporation | 5.39 Million USD | -7137.829% |
| Bioxytran, Inc. | 137.63 Thousand USD | -283338.44% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 15 Million USD | -2500.476% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | - USD | -Infinity% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 16.57 Million USD | -2253.091% |
| Adhera Therapeutics, Inc. | 79 Thousand USD | -493721.519% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 864.67 Thousand USD | -45017.31% |
| Innovation Pharmaceuticals Inc. | 7.51 Million USD | -5089.823% |
| Neutra Corp. | 2851.00 USD | -13683484.707% |
| Windtree Therapeutics, Inc. | 32.4 Million USD | -1103.848% |
| PureTech Health plc | 693.97 Million USD | 43.785% |
| Coeptis Therapeutics, Inc. | 8.07 Million USD | -4733.536% |
| IXICO plc | 15.84 Million USD | -2362.266% |
| IntelGenx Technologies Corp. | 8.28 Million USD | -4610.444% |
| Gelesis Holdings, Inc. | 103.32 Million USD | -277.569% |
| CSL Limited | 38.02 Billion USD | 98.974% |
| Cellectis S.A. | 333.99 Million USD | -16.804% |